Free Submission Public Relations &
Deutsch English

LCZ-696 (Chronic Heart Failure) - Forecast and Market Analysis to 2022

Global LCZ-696 market: Latest market analysis presented

Print article Print article
2014-02-17 03:34:04 - LCZ-696 (Chronic Heart Failure) - Forecast and Market Analysis to 2022 - a new market research report on

Novartis is developing an orally-administered, dual-acting ARNi, LCZ-696, as a first-in-class combination drug. LCZ-696 consists of a 1:1 mixture of the ARB valsartan and the novel neprilysin inhibitor AHU-377. Valsartan, marketed as Diovan for the treatment of hypertension and CHF, is a selective angiotensin II type 1 (AT1) inhibitor that causes vasodilation of the blood vessels and blood pressure reduction. AHU-377 is a pro-drug that is activated by de-ethylation via esterases to form the LBQ657 metabolite. LBQ657 inhibits the enzyme neprilysin, which results in decreased circulation levels of atrial natriuretic (ANP) and NT-proBNP, a biomarker for left ventricular wall stress (Solomon et al., 2012). By combining these two molecules, LCZ-696 may provide additional cardio-renal protection over the currently marketed drugs.




chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. We predict that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs.

However, the market entry of entry of Novartis´ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug´s efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact